Genky DrugStores Co., Ltd. (TYO:9267)
Japan
· Delayed Price · Currency is JPY 4,010.00
+45.00 (1.13%)
Apr 28, 2026, 3:30 PM JST
Genky DrugStores Income Statement
Financials in millions JPY. Fiscal year is July - June.
Millions JPY. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 20, 2026 | Jun '25 Jun 20, 2025 | Jun '24 Jun 20, 2024 | Jun '23 Jun 20, 2023 | Jun '22 Jun 20, 2022 | Jun '21 Jun 20, 2021 | 2020 - 2016 |
| Revenue | 215,113 | 200,786 | 184,860 | 169,059 | 154,639 | 142,376 | Upgrade
|
| Revenue Growth (YoY) | 9.94% | 8.62% | 9.35% | 9.32% | 8.61% | 15.19% | Upgrade
|
| Cost of Revenue | 171,185 | 159,896 | 147,239 | 134,505 | 123,685 | 112,087 | Upgrade
|
| Gross Profit | 43,928 | 40,890 | 37,621 | 34,554 | 30,954 | 30,289 | Upgrade
|
| Selling, General & Admin | 27,289 | 25,433 | 23,518 | 23,194 | 21,000 | 19,913 | Upgrade
|
| Other Operating Expenses | - | - | - | - | - | 339 | Upgrade
|
| Operating Expenses | 33,087 | 31,231 | 28,605 | 27,844 | 25,279 | 23,994 | Upgrade
|
| Operating Income | 10,841 | 9,659 | 9,016 | 6,710 | 5,675 | 6,295 | Upgrade
|
| Interest Expense | -273 | -216 | -103 | -70 | -59 | -55 | Upgrade
|
| Interest & Investment Income | 17 | 10 | 7 | 8 | 9 | 9 | Upgrade
|
| Other Non Operating Income (Expenses) | 435 | 445 | 347 | 430 | 437 | 352 | Upgrade
|
| EBT Excluding Unusual Items | 11,020 | 9,898 | 9,267 | 7,078 | 6,062 | 6,601 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 25 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 5 | 5 | -14 | 10 | 1 | - | Upgrade
|
| Asset Writedown | -10 | -3 | -286 | -386 | -9 | -56 | Upgrade
|
| Other Unusual Items | 4 | 2 | -165 | 1 | 4 | 117 | Upgrade
|
| Pretax Income | 11,019 | 9,902 | 8,802 | 6,703 | 6,083 | 6,662 | Upgrade
|
| Income Tax Expense | 3,205 | 2,836 | 2,478 | 1,939 | 1,663 | 1,831 | Upgrade
|
| Net Income | 7,814 | 7,066 | 6,324 | 4,764 | 4,420 | 4,831 | Upgrade
|
| Net Income to Common | 7,814 | 7,066 | 6,324 | 4,764 | 4,420 | 4,831 | Upgrade
|
| Net Income Growth | 15.92% | 11.73% | 32.75% | 7.78% | -8.51% | 75.35% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 30 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Change (YoY) | 0.30% | 0.13% | 0.09% | -0.02% | 0.03% | 0.10% | Upgrade
|
| EPS (Basic) | 256.72 | 232.49 | 208.18 | 156.89 | 145.59 | 159.15 | Upgrade
|
| EPS (Diluted) | 255.94 | 232.04 | 207.94 | 156.79 | 145.44 | 159.01 | Upgrade
|
| EPS Growth | 15.57% | 11.59% | 32.62% | 7.81% | -8.54% | 75.20% | Upgrade
|
| Free Cash Flow | - | -2,495 | 2,978 | -1,118 | -4,388 | 3,263 | Upgrade
|
| Free Cash Flow Per Share | - | -81.92 | 97.91 | -36.79 | -144.36 | 107.39 | Upgrade
|
| Dividend Per Share | 6.500 | 13.000 | 12.500 | 12.500 | 12.500 | 12.500 | Upgrade
|
| Dividend Growth | -49.02% | 4.00% | - | - | - | - | Upgrade
|
| Gross Margin | 20.42% | 20.36% | 20.35% | 20.44% | 20.02% | 21.27% | Upgrade
|
| Operating Margin | 5.04% | 4.81% | 4.88% | 3.97% | 3.67% | 4.42% | Upgrade
|
| Profit Margin | 3.63% | 3.52% | 3.42% | 2.82% | 2.86% | 3.39% | Upgrade
|
| Free Cash Flow Margin | - | -1.24% | 1.61% | -0.66% | -2.84% | 2.29% | Upgrade
|
| EBITDA | 17,678 | 15,951 | 14,582 | 11,665 | 10,267 | 10,353 | Upgrade
|
| EBITDA Margin | 8.22% | 7.94% | 7.89% | 6.90% | 6.64% | 7.27% | Upgrade
|
| D&A For EBITDA | 6,837 | 6,292 | 5,566 | 4,955 | 4,592 | 4,058 | Upgrade
|
| EBIT | 10,841 | 9,659 | 9,016 | 6,710 | 5,675 | 6,295 | Upgrade
|
| EBIT Margin | 5.04% | 4.81% | 4.88% | 3.97% | 3.67% | 4.42% | Upgrade
|
| Effective Tax Rate | 29.09% | 28.64% | 28.15% | 28.93% | 27.34% | 27.48% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.